MindBio raises US$256.7K as voice AI intoxication tool hits 83% accuracy
What's the deal? MindBio TherapeuticsDealroom has a profile for this one. Try Dealroom → has announced a nonbrokered private placement of up to US$256.7K, issuing up to 3,888,889 units at $0.09 each. Each unit pairs one common share with half a warrant, exercisable at $0.16 per share for 36 months after closing.
What's the endgame? MindBio, listed in Canada, Frankfurt, and the US, is building voice-analysis AI to detect drug and alcohol intoxication. It plans to pair its Voice AI software with an Edge AI detection kiosk for use in sectors such as mining, aviation, construction, and law enforcement, with an initial product operating in Spanish.
Why now? The company said its prediction models reached up to 83% accuracy "under certain testing conditions," exceeding some commercial cheek swab tests. It plans two to three more weeks of human testing before its first commercial pilot.
What could go wrong? The 83% figure is an interim test result, not proof of commercial readiness. MindBio says it is still validating the system against breath and oral-fluid tests, and the available reports do not establish independent, real-world performance.
Where the money goes: Proceeds are earmarked for general working capital, annual audit and legal expenses, and OTC and CSE listing costs.
The signal: This modest raise sits beside a string of earlier placements — up to US$806.7K floated in November 2025 and a US$476.7K round that upsized and closed near US$1.06M by April. The pattern points to continued development-stage financing rather than a demonstrated commercial rollout.
Read more: markets.financialcontent.com
Image credit: Generated with Gemini